HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB:RBCC) expects legislation in New Jersey giving additional credence and importance to Medication Assisted Treatment (MAT) programs to have a positive effect on patients and on distribution of Naltrexone, a drug MATs use to fight opioid addiction.
Governor Chris Christie signed into law Senate Bill 2381/Assembly Bill 3723, which allows persons who use MAT programs for substance abuse disorders to successfully complete drug court. Previously, those patients had to stop MAT before being permitted to successfully finish court. This legislation brings the Garden State in line with current clinical standards and has been hailed by many medical advocates and government officials.
RBCC CEO Kimberly Palmer praised the legislation and its potential to make a critical difference against substance abuse. “Now patients won’t have to stop treatment to complete court,” Palmer said. “They can continue treatment and repair their lives. This was much needed legislation. RBCC looks forward to working with New Jersey officials on making Naltrexone a bigger part of the state’s MATs and getting it in the hands of patients who will greatly benefit from its use.”
New Jersey has had success in curtailing addiction. It has reached seven out of 10 possible indicators denoting promising strategies to curb prescription drug abuse. However, the state also recently saw nearly 6,700 admissions to state-licensed or certified substance abuse treatment programs due to prescription drug abuse, a nearly 300 percent jump over the past decade.
“New Jersey has clearly made great strides,” Palmer said. “But there’s a long way yet to go. RBCC is eager to help the state reach its goals.”
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
